as you should know by now
always sell into the initial hyped pop
if you still want to be long, buy back after the plunge
With the pop today it may be Pharmer and his group shorting... I am not telling fairy tales here, these guys are low lifes...
The site is ipci dot ca. A Canadian site. Do what you can to stop these guys before its too late. Contact SEC. A number of people reported them in regards to IPCI, so if more people file complaints, the more likely the SEC will do something. It is a group of people led by the guy controlling the website I mentioned. If you read his posts, he feels he is doing nothing wrong. My opinion differs. Most importantly these criminals hurt the company. By holding PPS down on speculative stocks, it makes needed dilution much harder on current shareholders. mm_mom2 is right, they are accumulating now. They even say that on the IPCI site. When price tops out, they will short the daylights out and bring it down. Do what you can to get rid of these guys now. Believe me, you don't want these crooks here.
Just look up the symbol IPCI on yahoo. check out their past. I agree, I got duped by these guys. they do as "doyou" says. they run the price up get people to buy in then short the stock on news events driving the price down. in low float stocks its easily done with a few hundred thousand shares. right now they are accumulating. Notice the recent surge in Volume? get out when you can they will control price share, as they look to accumulate when the company needs to dilute so they can buy up cheap shares to cover their short positions.
Most of the time that is EGEN selling their shares. Cannot wait till the day they don't own 1 share.
Sentiment: Strong Buy
When Tardugno talks collaborations, he is talking about GEN-2 not GEN-1.
Not to mention statistically significant.
Celsion Plans to Initiate Clinical Trials this Year to Evaluate the 3-Way Combination in Recurrent Platinum Resistant Ovarian Cancer Patients
LAWRENCEVILLE, N.J., April 19, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that preclinical data for GEN-1 in combination with Avastin® and Doxil® was presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. GEN-1 is an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally to the tumor site. The full poster presentation can be found on Celsion's website at www.celsion.com.
The poster, entitled "Interleukin-12 Gene Therapy in Combination with Bevacizumab and PEGylated Liposomal Doxorubicin for Treatment of Disseminated Ovarian Cancer", highlighted results from a preclinical study evaluating GEN-1 combined with Avastin® and Doxil® in a SKOV3 human cell line implanted into immunocompromised (nude) mice compared to control. The results showed that the combination resulted in a statistically significant reduction of tumor burden of greater than 98% compared to control, and a statistically significant 92% reduction in tumor burden compared to Avastin® plus Doxil® alone. In contrast, Avastin® and GEN-1 produced a 39% and 50% reduction in tumor burden, respectively. The combination of GEN-1 with Avastin® and Doxil® was well-tolerated with no systemic toxicities.
These preclinical data are consistent with the mechanism of action for GEN-1, which exhibits certain anti-angiogenic properties in addition to its well-characterized immunomodulatory activities.
"These remarkable preclinical results underscore the synergistic activity of GEN-1 and Avastin® plus Doxil®, with dramatic reductions in tumor volume compared to either therapy alone. The data from this trial, together with the scientific rationale for our approach, reinforce our confidence in the potential of this combination to improve outcomes for patients with platinum-resistant ovarian cancer," said Khursheed Anwer, PhD, executive vice president and chief science officer of Celsion.
Read more: http://www.kctv5.com/story/31759789/celsion-presents-compelling-data-at-aacr-2016-demonstrating-synergistic-anti-cancer-effect-of-gen-1-il-12-immunotherapy-plus-avastin-and-doxil#ixzz46HKMvEaE
Sentiment: Strong Buy